Daiichi Sankyo: DS-6000 Suggests Early Clinical Activity in Patients with Advanced Ovarian Cancer or Renal Cell Carcinoma

Initial dose escalation results from first-in-human phase 1 trial of DS-6000, Daiichi Sankyo's fifth DXd ADC in clinical development, featured in oral presentation at ASCO Dose expansion phase

Related Keywords

Japan ,Tennessee ,United States ,Nashville ,American ,Masashi Kawase ,Simone Jendsch Dowe ,Samantha Maxwell ,Daiichi Sankyo ,Daiichi Sankyo Europe Gmb ,Sarah Mcgovern ,Sarah Cannon Development Innovations ,Gynecologic Cancer Research ,American Society Of Clinical Oncology ,Oncology Development ,Sarah Cannon Research Institute At Tennessee Oncology ,Daiichi Sankyo Inc ,Sarah Cannon Research Institute ,Healthcare Cancer Institute ,Sarah Cannon Development Innovations In Nashville ,Sustainable Development Of Society ,Daiichi Sankyo Co Ltd ,Innovative Global Healthcare Company ,Sarah Cannon ,American Society ,Clinical Oncology ,Gynecologic Cancer Intergroup ,Erika Hamilton ,Breast Cancer ,Tennessee Oncology ,Gilles Gallant ,Senior Vice President ,Global Head ,Ovarian Cancer ,Renal Cell ,Global Healthcare Company Contributing ,Sustainable Development ,Cannon Research Institute ,Cancer Institute ,Sarah Cannon Development ,Intj Mol Sci ,Stat Facts ,Renal Pelvis ,Population Fact ,Updated November ,Curr Opin Oncol ,Sankyo Europe Gmbh ,Daiichi ,Sankyo ,000 ,Uggests ,Early ,Linical ,Activity ,Patients ,Dvanced ,Ovarian ,Dancer ,Prenal ,Fell ,Arcinoma ,